Trial Radar IA | ||
|---|---|---|
Lo studio clinico NCT06445192 per Carcinoma Polmonare è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui. | ||
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca
Università statale dell'OhioEvaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT06445192 è uno studio interventistico per Carcinoma Polmonare, attualmente in arruolamento. Avviato il 3 novembre 2023, prevede di arruolare 88 partecipanti. Sotto la guida di l'Università statale dell'Ohio, dovrebbe concludersi entro il 31 dicembre 2025. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 3 giugno 2025.
Sommario breve
This phase II trial evaluates how a virtually supervised exercise intervention in combination with group counseling affects inflammation and the bacterial composition (microbiome) of the gut in smokers who are at high risk for lung cancer. Physical exercise has been shown to reduce lung cancer development and to have beneficial effects on the gut microbiome and inflammation. Group counseling may promote adherence to the exercise intervention by empowering participants to exert greater control over their behavior and environment. This clinical trial may help researchers understand how exercise impacts inflammation and the microbiome in people at risk for lung cancer and whether or not exercise with counseling can improve health outcomes in high-risk individuals.
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To evaluate the feasibility and preliminary efficacy of establishing a multi-component virtually-delivered exercise intervention trial with longitudinal biomarker and microbiome collection in the Ohio State University Lung Cancer Screening Clinic (OSULCSC).
II. To determine the impact of the multi-component virtually-delivered exercise intervention on the microbiome and inflammatory biomarkers.
OUTLINE: Participants are randomized to 1 of 2 groups.
GROUP I: Participants receive the supervised aerobic and resistance exercise intervention over 1 hour via telehealth twice a week (BIW) in weeks 1-8 and once a week (QW) in weeks 9-12 and then continue with unsupervised exercise sessions BIW in weeks 13-52. Participants also attend group counseling sessions over 1 hour QW in weeks 1-8 and bi-weekly in weeks 9-12. Participants also wear a Fitbit throughout the trial and undergo collection of blood samples at baseline and follow up.
GROUP II: Participants receive usual care consisting of education on standard recommendations for physical activity, the benefits of exercise, and an example of a light walking program. Participants also wear a Fitbit throughout the trial and undergo collection of blood samples at baseline and follow up.
After completion of study intervention, participants are followed up at 12 weeks and 1 year.
Titolo ufficiale
The BE FIT Study: Feasibility of an Exercise Intervention on Microbiome and Immune Function in a High-Risk Cohort for Lung Cancer
Condizioni
Carcinoma PolmonareAltri ID dello studio
Numero NCT
Data di inizio (effettiva)
2023-11-03
Ultimo aggiornamento pubblicato
2025-06-03
Data di completamento (stimata)
2025-12-31
Arruolamento (previsto)
88
Tipo di studio
Interventistico
FASE
N.D.
Stato
In arruolamento
Scopo principale
Prevenzione
Allocazione
Randomizzato
Modello di intervento
In parallelo
Mascheramento
Singolo
Bracci / Interventi
| Gruppo/Braccio di partecipanti | Intervento/Trattamento |
|---|---|
SperimentaleGroup I (exercise intervention) Participants receive the supervised aerobic and resistance exercise intervention over 1 hour via telehealth BIW in weeks 1-8 and QW in weeks 9-12 and then continue with unsupervised exercise sessions BIW in weeks 13-52. Participants also attend group counseling sessions over 1 hour QW in weeks 1-8 and bi-weekly in weeks 9-12. Participants also wear a Fitbit throughout the trial and undergo collection of blood samples at baseline and follow up. | Raccolta di biospecimen Undergo collection of blood samples Consulenza sull'esercizio fisico Attend group counseling Intervento di esercizio Receive aerobic and resistance exercise intervention via telehealth Utilizzo e valutazione del dispositivo medico Wear Fitbit Test delle prestazioni fisiche Ancillary studies Somministrazione del questionario Ancillary studies Telemedicina Receive aerobic and resistance exercise intervention via telehealth |
Comparatore attivoGroup II (usual care) Participants receive usual care consisting of education on standard recommendations for physical activity, the benefits of exercise, and an example of a light walking program. Participants also wear a Fitbit throughout the trial and undergo collection of blood samples at baseline and follow up. | Migliore pratica Receive usual care Raccolta di biospecimen Undergo collection of blood samples Utilizzo e valutazione del dispositivo medico Wear Fitbit Test delle prestazioni fisiche Ancillary studies Somministrazione del questionario Ancillary studies |
Esito primario
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Number of patients recruited to virtually-delivered exercise intervention (feasibility) | To evaluate the feasibility and preliminary efficacy of establishing a multi-component virtually-delivered exercise intervention trial with longitudinal biomarker and microbiome collection in the Ohio State University Lung Cancer Screening Clinic (OSULCSC) | Up to 1 year |
Proportion of patients who achieve study adherence (feasibility) based on attendance to the exercise program sessions and biospecimens submitted. | Study adherence is defined as a) the proportion of patients attending at least 20 out of 24 sessions for the 12-week program and b) the percentage of biospecimen samples collected at the post program period (12 weeks). This study will be considered feasible if the compliance rate for both of these combined is 75% or more. Descriptive statistics will be used to examine the distribution of all patient and treatment characteristics, including compliance. | During 12-week program |
Assess the number of participants with a change in inflammatory biomarkers | Will assess the effect of the intervention on inflammatory markers of C-reactive protein and IL-6 separately using linear mixed models with the biomarker serving as the outcome variable. Will also assess the changes in the biomarkers across time in each intervention group. | Baseline to post-intervention (12 weeks) |
Microbe relative abundances | Will assess the effect of the intervention on the diversity and relative abundances of individual microbes. Will compare everyone's post-intervention time point to baseline in control and the exercise interventions cohorts, applying linear or generalized mixed-effects models for the diversity or individual microbes. | Baseline to post-intervention (12 weeks) |
Criteri di eleggibilità
Età idonea
Adulto, Adulto anziano
Età minima
40 Years
Sessi idonei
Tutti
Accetta volontari sani
Sì
- 50-77 years of age
- Current or former smoker with 20-pack year smoking history and within the last 15 years
- Fewer than 150 minutes of participation in moderate intensity physical activity each week
- All participants must be free of severe heart, respiratory (e.g. chronic obstructive pulmonary disease [COPD]), or systemic disease that would make moderate intensity exercise participation unsafe
- Willing to sign an informed consent
- Person undergoing treatment for cancer in any form
- Person plans to enter smoking cessation or change status
Università statale dell'Ohio455 studi clinici attivi da esplorareParte responsabile dello studio
Marisa Bittoni, Investigatore principale, Principal Investigator, Ohio State University Comprehensive Cancer Center
Contatti principali dello studio
Contatto: The Ohio State Comprehensive Cancer Center, 800-293-5066, [email protected]
1 Centri dello studio in 1 paesi
Ohio
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States
Marisa Bittoni, PhD, Contatto, 614-206-3518, [email protected]
Marisa Bittoni, PhD, Investigatore principale
In arruolamento